<DOC>
	<DOCNO>NCT02742779</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple orally ascend dos GDC-0310 administer healthy participant 4 part include Part 1- single dose ( SD ) part use powder-in-capsule ( PIC ) formulation , Part 2- multiple dose ( MD ) part use PIC formulation , Part 3- SD part use solution formulation , Part 4- MD part use solution formulation . Effects food pharmacokinetics ( PK ) also explore .</brief_summary>
	<brief_title>A Study Determine Safety , Tolerability , Pharmacokinetics GDC-0310 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Female participant nonchildbearing potential must meet criterion define protocol Body mass index within range 18.0 30.0 kilogram per meter square ( kg/m^2 ) , inclusive , minimum weight 50.0 kg Have clinically significant medical condition ( e.g. , hypertension ; diabetes ; impaired cardiac , renal hepatic function ; hyperthyroidism hypothyroidism ; neurological disorder ; pain condition ; hematologic disorder ; psychiatric disorder require chronic medication ) include medical condition require treatment medication ( study drug medication specifically allow protocol ) participation study Evidence hepatic impairment include abnormal level ( i.e. , great [ &gt; ] 1 × upper limit normal ) alkaline phosphatase , gamma glutamyl transpeptidase , alanine transaminase , aspartate aminotransferase bilirubin Evidence clinically significant renal impairment define &gt; 1.3 × upper limit normal creatinine History presence alcoholism alcohol substance abuse ( include nicotine caffeine ) within previous 2 year routinely consume 2 alcoholcontaining beverage per day 10 unit alcohol per week ( 1 unit =150 milliliter ( mL ) wine , 360 mL beer , 45 mL 40 percent ( % ) alcohol ) Have positive urine drug test screening checkin point study Are habituate analgesic drug ( i.e. , routine use oral analgesic 5 time per week ) history chronic pain require opiate use Have use tobacco nicotinecontaining product within 3 month study drug administration Have clinically significant abnormal laboratory value determine principal investigator Have use prescription overthecounter medication supplement within 14 day 5 time elimination halflife ( whichever longer ) administration study drug end participation study History seizure , include first degree relative History heritable myopathy , weakness , paralysis , include first degree relative indicative familial periodic paralysis Current treatment medication well know prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>